Étiquette : 5-HT1A

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders : Molecular Mechanisms and Targets, Rosa Maria Vitale et al., 2021

The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets Rosa Maria Vitale, Fabio Arturo Iannotti and Pietro Amodeo International journal of Molecular Sciences, 2021, 22, 4876, 1-20. Doi : 10.3390/ijms22094876   Abstract : Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. Albeit the molecular mechanisms responsible for the therapeutic effects of CBD have yet to be fully elucidated, many [...]

Lire la suite

The nephrologist’s guide to cannabis and cannabinoids, Joshua L. Rein, 2020

The nephrologist’s guide to cannabis and cannabinoids Joshua L. Rein   Purpose of review Cannabis (marijuana, weed, pot, ganja, Mary Jane) is the most commonly used federally illicit drug in the United States. The present review provides an overview of cannabis and cannabinoids with relevance to the practice of nephrology so that clinicians can best take care of patients. Recent findings Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. Cannabis does not seem to affect kidney function in healthy individuals. However, renal function should be [...]

Lire la suite

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice, Andreza B. Sonego et al., 2016

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042   Highlights  Cannabidiol (CBD) attenuated haloperidol-induced catalepsy.  CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol.  CBD effects were blocked by 5-HT1A receptor antagonist.   Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]

Lire la suite

Modern Clinical Research on LSD, Matthias E Liechti, 2017

Modern Clinical Research on LSD Matthias E Liechti Neuropsychopharmacology, 2017, 42, 2114–2127. doi : 10.1038/npp.2017.86   All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left [...]

Lire la suite

CBD & the Psychedelic Receptor, Lex Pelger, projectCBD.org, 2019

CBD & the Psychedelic Receptor Lex Pelger On March 11, 2018 (Updated on April 16, 2019) https://www.projectcbd.org/science/cbd-psychedelic-receptor CBD and LSD bind to the same serotonin receptor, which mediates psychedelic altered states. But cannabidiol has anti-psychotic properties and doesn't cause hallucinations. In a shorthand that drives scientists mad, serotonin is often called ‘the neurotransmitter of happiness.’ This tag is especially troublesome as more and more flaws become apparent in the ‘serotonin hypothesis’ of depression – the idea that depression is caused by a serotonin deficit, which a pill (a serotonin reuptake inhibitor) could correct.1  Serotonin is a complex molecule in the brain and the [...]

Lire la suite

Clinical potential of psilocybine as a treatment for mental health conditions, Jeremy Daniel & Margaret Haberman, 2017.

Clinical potential of psilocybine as a treatment for mental health conditions Jeremy Daniel & Margaret Haberman Mental Health Clinician, 2017, Vol. 7, No. 1, pp. 24-28 https://doi.org/10.9740/mhc.2017.01.024   Abstract Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including [...]

Lire la suite

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens, Adam L. Halberstadt & Mark A. Geyer, 2011

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens Adam L. Halberstadt & Mark A. Geyer Neuropharmacology, 2011, 61, (3), 364–381. doi:10.1016/j.neuropharm.2011.01.017.   Abstract Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT2 receptor agonists, whereas the indoleamines are relatively nonselective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the [...]

Lire la suite

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers, Boris B. Quednow et al., 2012

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers Boris B Quednow, Michael Kometer, Mark A Geyer and Franz X Vollenweider Neuropsychopharmacology, 2012, 37, 630–640 doi:10.1038/npp.2011.228   The serotonin-2A receptor (5-HT2AR) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients. The hallucinogen psilocybin disrupts automatic forms of sensorimotor gating and response inhibition in humans, but it is unclear so far whether the 5-HT2AR or 5-HT1AR agonist properties of its bioactive metabolite psilocin account for these effects. Thus, we investigated whether psilocybin-induced deficits in automatic and controlled inhibition in healthy [...]

Lire la suite

Evidences for the Anti-panic Actions of Cannabidiol, Vanessa P. Soares and Alline C. Campos, 2017

Evidences for the Anti-panic Actions of Cannabidiol Vanessa P. Soares and Alline C. Campos Current Neuropharmacology, 2017, 15, 291-299 DOI : 10.2174/1570159X14666160509123955   Abstract : Background : Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the [...]

Lire la suite

Long-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up, Rafael G. dos Santos et al., 2018,

Long-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E.C. Hallak Archive of Clinical Psychiatry, 2018, 45, 1, 22-4 DOI: 10.1590/0101-60830000000149 Abstract Background : Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for [...]

Lire la suite